Introduction: Febrile neutropenia (FN) is one of the complications of chemotherapy that can increase the risk of infection and mortality. Granulocyte colony-stimulating factors (G-CSFs) are used in practice to prevent and treat episodes of neutropenia. The use of G-CSFs in children with cancer has not been studied much for primary prophylaxis of FN.
Areas Covered: Current data suggest that G-CSFs have a similar pharmacokinetic profile in children and adults. Clinical trials published from 2002 to 2021 using G-CSFs in pediatric cancer patients were reviewed. All evaluated clinical trials used a dosage of 5 mcg/kg of filgrastim daily until neutrophil recovery or a single dose of 100 mcg/kg pegfilgrastim. Filgrastim demonstrated the benefit in decreasing the duration of fever, hospital stay, and antibiotic use in high-risk neuroblastoma patients. Pegfilgrastim showed similar efficacy in reducing the occurrence of FN and infections, with bone pain as an adverse effect.
Expert Opinion: Filgrastim 5 mcg/kg/day or pegfilgrastim 100 mcg/kg single dose is appropriate when given at least 24 hours or after the chemotherapy in pediatric patients who weigh 45 kg or more. More prospective randomized trials are necessary to further investigate the efficacy and safety of G-CSFs in children with different types of cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17512433.2022.2110066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Granulocyte Colony Stimulating Factor in Mitigating the Risk of Recurrent Miscarriages: A Comprehensive Review and Meta-Analysis.
Reprod Sci
December 2024
Reproductive Immunization Center, Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital), NHC Key Laboratory of Male Reproduction and Genetics, Guangzhou, Guangdong, 510660, China.
Granulocyte colony-stimulating factor (G-CSF), a pivotal hematopoietic cytokine, has been noted for its potential to bolster embryo implantation and augment endometrial receptivity. The present meta-analysis endeavors to evaluate the therapeutic efficacy of G-CSF in mitigating the incidence of recurrent miscarriages, thereby enriching the clinical evidence supporting its use in treatment protocols. Our exhaustive literature search, concluded on August 25, 2024, spanned across various databases including PubMed, Medline, Cochrane Library, Web of Science, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Weipu, and Wanfang, to identify and analyze randomized controlled trials (RCTs) that assessed the impact of G-CSF on recurrent miscarriage.
View Article and Find Full Text PDFEffectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
Int J Clin Oncol
August 2024
Department of Orthopaedic Surgery, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?".
Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019.
Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children.
Expert Rev Clin Pharmacol
August 2022
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
Introduction: Febrile neutropenia (FN) is one of the complications of chemotherapy that can increase the risk of infection and mortality. Granulocyte colony-stimulating factors (G-CSFs) are used in practice to prevent and treat episodes of neutropenia. The use of G-CSFs in children with cancer has not been studied much for primary prophylaxis of FN.
View Article and Find Full Text PDFChemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Oncologist
August 2022
Cancer Centre, Clinique de Genolier, Genolier, Switzerland.
Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive chemotherapy. This review provides an up-to-date assessment of the patient and cost burden of chemotherapy-induced neutropenia/FN in the US, and summarizes recommendations for FN prophylaxis, including the interim guidance that was recommended during the coronavirus disease 2019 (COVID-19) pandemic. This review indicates that neutropenia/FN place a significant burden on patients in terms of hospitalizations and mortality.
View Article and Find Full Text PDFThe effect of granulocyte colony-stimulating factors on survival parameters in pediatric patients with acute lymphoblastic leukemia: A retrospective study.
Transfus Apher Sci
February 2022
Department of Pediatric Hematology and Oncology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.
Objective: There is a paucity of data concerning the use of granulocyte colony-stimulating factors (G-CSFs) in pediatric patients with acute lymphoblastic leukemia (ALL). The aim of the present study was to evaluate the effect of G-CSF use on relapse-free and overall survival in 358 consecutive, newly diagnosed pediatric ALL patients uniformly treated at the same institution between April 2012 and April 2020.
Materials And Methods: Patients were evaluated in two separate periods, based on the G-CSF treatment approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!